Oryzon Genomics S.A.
ORYZF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$253.86M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $253.86 Million |
|---|---|
| Enterprise Value | $245.01 Million |
| Earnings per Share | $-0.04 |
| Beta | 0.45 |
| Outstanding Shares | 77,513,372 |
Return
| Return on Equity | -1.97% |
|---|---|
| Return on Assets | -1.68% |
| Return on Invested Capital | -5.52% |
Valuation & Multiples
| P/E Ratio | -80.13 |
|---|---|
| PEG | -22.66 |
| Price to Sales | - |
| Price to Book Ratio | 3.1 |
| Enterprise Value to Revenue | 28.19 |
| Enterprise Value to EBIT | -34.15 |
| Enterprise Value to Net Income | -104 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 27, 2026
EPS Estimate
$-0.06
Consensus analyst estimateRevenue Estimate
$9.94 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$-0.07
Consensus analyst estimateRevenue Estimate
$8.96 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Oryzon Genomics S.A.
46 employees
CEO: Carlos Manuel Buesa Arjol
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical firm dedicated to the discovery and advancement of epigenetics-based therapies. Its primary focus is on treating cancer and central nervous system (CNS) disorders. The company's ...